KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Gross Profit (2016 - 2025)

Pacific Biosciences Of California has reported Gross Profit over the past 16 years, most recently at $16.6 million for Q4 2025.

  • Quarterly results put Gross Profit at $16.6 million for Q4 2025, up 64.7% from a year ago — trailing twelve months through Dec 2025 was $45.8 million (up 22.79% YoY), and the annual figure for FY2025 was $45.8 million, up 22.79%.
  • Gross Profit for Q4 2025 was $16.6 million at Pacific Biosciences Of California, up from $15.9 million in the prior quarter.
  • Over the last five years, Gross Profit for PACB hit a ceiling of $17.9 million in Q3 2023 and a floor of -$1.4 million in Q1 2025.
  • Median Gross Profit over the past 5 years was $13.5 million (2022), compared with a mean of $12.0 million.
  • Peak annual rise in Gross Profit hit 147.29% in 2025, while the deepest fall reached 112.15% in 2025.
  • Pacific Biosciences Of California's Gross Profit stood at $16.8 million in 2021, then tumbled by 69.34% to $5.1 million in 2022, then surged by 86.21% to $9.6 million in 2023, then increased by 5.09% to $10.1 million in 2024, then soared by 64.7% to $16.6 million in 2025.
  • The last three reported values for Gross Profit were $16.6 million (Q4 2025), $15.9 million (Q3 2025), and $14.7 million (Q2 2025) per Business Quant data.